Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIMERA study
2023-509584-24-01Phase 2Authorised
- Sponsor
- Istituto Oncologico Veneto
- Start
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in pleural mesothelioma, sponsored by Istituto Oncologico Veneto. Primary endpoint: Pathological complete response (pCR). Planned start Aug 2024; status: authorised.
02
Drugs
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2023-509584-24-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509584-24-01.